PubMed · 1995 · 42 citations · 0 references
PharmacyPharmacologyPharmacotherapyPharmaceutical ToxicologyPoisoning DiagnosisPoisoning ManagementOrganophosphate ToxicologyPralidoxime TherapyIntravenous Pralidoxime AdministrationOrganophosphate Poisoning TreatmentPralidoxime Combination TherapyPralidoxime Dosing RegimensPralidoxime EfficacyPralidoxime Infusion TherapyRelative Risk EstimationTiming Of Pralidoxime Administration
Seventy two patients admitted to the Intensive Care Unit following ingestion of organophosphorus compounds were studied prospectively with two different doses of pralidoxime (PAM). One group received 1 gm immediately after admission and no further PAM and the other group received infusion of PAM, 1 gm 8 hourly for four days (total 12 gms). The incidence of type II paralysis or intermediate syndrome was 47%. We observed a higher incidence in the 4 days of infusion of PAM group (61%) (20 patients) as compared to the single Bolus dose group (39%) (13 patients). Relative risk 1.48 (confidence interval = 0.9-2.4).